2m 2m 2m 2m 2m 2m 2m
Syndax Pharmaceu (SNDX)
NASDAQ
$19.65-$0.005 (-0.03%)
Price as of Aug 21, 2026 7:30 PM EDT- $1.8BMarket Cap
- 21.00%1-Year Change
- BiotechnologyIndustry
Syndax Pharmaceu (SNDX)
$19.65-$0.005 (-0.03%)
Top Holders
Institutional
Mutual Funds
Holder | Ownership %
| Shares Held | Change (Shares, %) | Report Date |
|---|---|---|---|---|
BLACKROCK FUNDING, INC. /DE | 10.20% | 9.0M | +794,899 (+8.80%) | Dec 31, 2024 |
BLACKROCK, INC. | 10.18% | 9.0M | +765,580 (+8.49%) | Jun 30, 2026 |
KYNAM CAPITAL MANAGEMENT, LP | 9.09% | 8.1M | 0 (0.00%) | Jun 30, 2026 |
BLACKROCK INC. | 8.92% | 7.9M | +354,334 (+4.48%) | Jun 30, 2024 |
VANGUARD GROUP INC | 7.03% | 6.2M | +1.1M (+17.52%) | Dec 31, 2025 |
GOLDMAN SACHS GROUP INC | 6.61% | 5.9M | +864,478 (+14.75%) | Jun 30, 2026 |
STATE STREET CORP | 6.39% | 5.7M | +1.2M (+21.71%) | Jun 30, 2026 |
Holder | Ownership %
| Shares Held | Change (Shares, %) | Report Date |
|---|---|---|---|---|
VANGUARD INDEX FUNDS | 4.21% | 3.7M | +66,503 (+1.78%) | Mar 31, 2026 |
VANGUARD SPECIALIZED FUNDS | 3.37% | 3.0M | 0 (0.00%) | Apr 30, 2026 |
SPDR SERIES TRUST | 2.64% | 2.3M | 0 (0.00%) | Apr 30, 2026 |
Manager Directed Portfolios | 1.54% | 1.4M | 0 (0.00%) | May 31, 2026 |
MUTUAL FUND SERIES TRUST | 1.40% | 1.2M | 0 (0.00%) | Mar 31, 2026 |
FRANKLIN STRATEGIC SERIES | 1.19% | 1.1M | -217,973 (-20.64%) | Apr 30, 2026 |
TIAA-CREF FUNDS | 1.13% | 997,514 | +18,965 (+1.90%) | Apr 30, 2026 |
Current Ownership Distribution
- Institutions1.6B (84.35%)
- Mutual Funds287.9M (15.29%)
- Insiders6.7M (0.36%)
- Other0 (0.00%)
Insider Transactions
- 0.36% (6.7M)Current InsiderOwnership (%, shares)
- 0Number of InsiderBuying (last 12 months)
- $0.00Amount of InsiderBuying (last 12 months)
- 3Number of InsiderSelling (last 12 months)
- $16.2MAmount of InsiderSelling (last 12 months)
Insider Name & Title | Type | Date
| Transaction Value | Shares | Share Price | Shares After Transactions |
|---|---|---|---|---|---|---|
Botwood Nicholas A.J. Head of R&D, CMO | Exempt | Jun 12, 2026 | $0.00 | 31,235 | $0.00 | 0 |
Botwood Nicholas A.J. Head of R&D, CMO | Exempt | Jun 12, 2026 | $431,667.70 | 31,235 | $13.82 | 92,120 |
Botwood Nicholas A.J. Head of R&D, CMO | Sell | Jun 12, 2026 | $566,602.90 | 31,235 | $18.14 | 60,885 |
Botwood Nicholas A.J. Head of R&D, CMO | Exempt | Jun 11, 2026 | $311,157.30 | 22,515 | $13.82 | 95,165 |
Botwood Nicholas A.J. Head of R&D, CMO | Sell | Jun 11, 2026 | $617,040.00 | 34,280 | $18.00 | 60,885 |
Botwood Nicholas A.J. Head of R&D, CMO | Exempt | Jun 11, 2026 | $0.00 | 22,515 | $0.00 | 0 |
Metzger Michael A Chief Executive Officer | Sell | Feb 09, 2026 | $360,819.45 | 17,159 | $21.03 | 491,690 |
Goldan Keith A. Chief Financial Officer | Sell | Feb 06, 2026 | $42,930.84 | 2,082 | $20.62 | 143,839 |
Legault Pierre | Award | Feb 04, 2026 | $0.00 | 24,000 | $0.00 | 114,000 |
Rizo Aleksandra | Award | Feb 04, 2026 | $0.00 | 24,000 | $0.00 | 49,000 |
Katkin Keith | Award | Feb 04, 2026 | $0.00 | 24,000 | $0.00 | 124,000 |
Jarrett Jennifer | Award | Feb 04, 2026 | $0.00 | 24,000 | $0.00 | 114,000 |
Botwood Nicholas A.J. Head of R&D, CMO | Award | Feb 04, 2026 | $3.0M | 144,700 | $20.43 | 144,700 |
Podlesak Dennis | Award | Feb 04, 2026 | $0.00 | 48,000 | $0.00 | 239,763 |
Botwood Nicholas A.J. Head of R&D, CMO | Award | Feb 04, 2026 | $0.00 | 24,000 | $0.00 | 59,165 |
Goldan Keith A. Chief Financial Officer | Award | Feb 04, 2026 | $2.4M | 118,000 | $20.43 | 118,000 |
Botwood Nicholas A.J. Head of R&D, CMO | Award | Feb 04, 2026 | $0.00 | 36,000 | $0.00 | 95,165 |
Goldan Keith A. Chief Financial Officer | Award | Feb 04, 2026 | $0.00 | 21,500 | $0.00 | 115,171 |
Goldan Keith A. Chief Financial Officer | Award | Feb 04, 2026 | $0.00 | 30,750 | $0.00 | 145,921 |
Goldan Keith A. Chief Financial Officer | Other | Jan 30, 2026 | $10,337.12 | 1,219 | $8.48 | 93,671 |
Metzger Michael A Chief Executive Officer | Exempt | Sep 08, 2025 | $0.00 | 157,307 | $0.00 | 0 |
Metzger Michael A Chief Executive Officer | Exempt | Sep 08, 2025 | $1.7M | 157,307 | $10.90 | 455,968 |
Metzger Michael A Chief Executive Officer | Sell | Sep 08, 2025 | $2.6M | 157,307 | $16.41 | 298,661 |
Podlesak Dennis | Exempt | Aug 18, 2025 | $0.00 | 19,200 | $0.00 | 0 |
Podlesak Dennis | Exempt | Aug 18, 2025 | $138,240.00 | 19,200 | $7.20 | 210,963 |
Podlesak Dennis | Sell | Aug 18, 2025 | $304,170.24 | 19,200 | $15.84 | 191,763 |
Podlesak Dennis | Exempt | Aug 15, 2025 | $138,240.00 | 19,200 | $7.20 | 210,963 |
Podlesak Dennis | Sell | Aug 15, 2025 | $298,408.32 | 19,200 | $15.54 | 191,763 |
Podlesak Dennis | Exempt | Aug 15, 2025 | $0.00 | 14,400 | $0.00 | 0 |
Podlesak Dennis | Exempt | Aug 15, 2025 | $0.00 | 4,800 | $0.00 | 0 |